E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis

Table 2 E-cadherin expression in early stage IDCs

Characteristics	No. of patients	E-cadherin		χ ² (P value)
Characteristics	No. of patients	Negative/low	Positive	χ ² (P value)
Histologic grade
I	13	2	11	0.79 (0.673)
II	107	17	90
III	36	8	28
Tumor stage
T1	77	15	62	0.50 (0.479)
T2	79	12	67	0.50 (0.479)
Nodal stage
Negative	96	20	76	2.17 (0.141)
Positive	60	7	53	2.17 (0.141)
TNM stage
I	50	11	39	1.13 (0.287)
II	106	16	90	1.13 (0.287)
ER
Negative	52	13	39	3.23 (0.073)
Positive	104	14	90	3.23 (0.073)
PR
Negative	82	16	66	0.59 (0.444)
Positive	74	11	63	0.59 (0.444)
HER2
Negative	129	24	105	0.43 (0.512)
Positive	27	3	24	0.43 (0.512)
Ki67
Negative	40	6	34	0.20 (0.655)
Positive	116	21	95	0.20 (0.655)
Molecular subtypes
Luminal A	30	3	27	7.85 (0.049)
Luminal B	74	11	63
HER2-enriched	14	1	13
TNBC	38	12	26

IDC invasive ductal carcinoma of the breast, TNBC triple-negative breast cancer

ISSN: 1477-7819